Angiogenesis inhibitors in the treatment of cancer (Q36222054)

12 August 2017

1 reference

title

Angiogenesis inhibitors in the treatment of cancer (English)

1 reference

12 August 2017

main subject

angiogenesis inhibitor

1 reference

Jay Rhee

1

1 reference

12 August 2017

Paulo M Hoff

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

Expert Opinion on Pharmacotherapy

12 August 2017

published in

1 reference

12 August 2017

volume

6

1 reference

12 August 2017

issue

10

1 reference

12 August 2017

page(s)

1701-1711

1 reference

Tumor angiogenesis: therapeutic implications

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Induction of angiogenesis during the transition from hyperplasia to neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

VEGF and the quest for tumour angiogenesis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Clinical applications of angiogenic growth factors and their inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Angiogenesis: now and then.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

VEGF-receptor signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Endogenous angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

von Hippel-Lindau disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Expression of vascular endothelial growth factor receptors in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.6.10.1701

10.1517/14656566.6.10.1701

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference